Libtayo Archives -

There’s no shortage of cancer immunotherapies trying to knock Merck & Co’s Keytruda off the top of the

ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda

https://pharmaphorum.com/news/esmo21-libtayo-extends-survival-in-first-line-nsclc-challenging-keytruda/

Sanofi and Regeneron’s latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche

Sanofi and Regeneron eye Libtayo challenge to Keytruda in first-line lung cancer

https://pharmaphorum.com/news/sanofi-regeneron-eye-libtayo-challenge-to-merck-in-first-line-lung-cancer/

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for

Libtayo gets a double with EU approvals in skin, lung cancer

https://pharmaphorum.com/news/libtayo-gets-a-double-with-eu-approvals-in-skin-lung-cancer/

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a

Sanofi, Regeneron prep filings for Libtayo in cervical cancer

https://pharmaphorum.com/news/sanofi-regeneron-prep-filings-for-libtayo-in-cervical-cancer/

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated

Sanofi’s immunotherapy Libtayo gets FDA approval in first line lung cancer

https://pharmaphorum.com/news/sanofis-immunotherapy-libtayo-gets-fda-not-in-first-line-lung-cancer/

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech

Regeneron pairs with BioNTech on melanoma immunotherapy

https://pharmaphorum.com/news/regeneron-pairs-with-biontech-on-melanoma-immunotherapy/

Regeneron has doubled down in its ongoing collaboration with ISA Pharma, taking a bigger stake in the Dutch

Regeneron gets closer to ISA Pharma with new immuno-oncology alliance

https://pharmaphorum.com/news/regeneron-gets-closer-to-isa-pharma-with-new-immuno-oncology-alliance/

Libtayo